{"id":"https://openalex.org/W1491092293","doi":null,"title":"Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.","display_name":"Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.","publication_year":2008,"publication_date":"2008-12-01","ids":{"openalex":"https://openalex.org/W1491092293","mag":"1491092293","pmid":"https://pubmed.ncbi.nlm.nih.gov/19260377"},"language":"en","primary_location":{"id":"pmh:oai:mattioli1885journals.com:article/1246","doi":null,"is_oa":true,"landing_page_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/1246","pdf_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/download/1246/891","source":{"id":"https://openalex.org/S4393915150","display_name":"Acta bio-medica dell'Ateneo parmense/Acta biomedica","issn_l":"0392-4203","issn":["0392-4203","2531-6745"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","norway-1","poland-20","russia-white-list-2"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"0392-4203","raw_type":"info:eu-repo/semantics/article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/download/1246/891","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5010127891","display_name":"Antonio Nicolucci","orcid":"https://orcid.org/0000-0002-5939-6850","observed_orcids":["https://orcid.org/0000-0002-5939-6850"]},"institutions":[{"id":"https://openalex.org/I4210110338","display_name":"Mario Negri Sud Foundation","ror":"https://ror.org/01qd3xc93","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210110338"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Antonio Nicolucci","raw_affiliation_strings":["Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy. nicolucci@negrisud.it"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy. nicolucci@negrisud.it","institution_ids":["https://openalex.org/I4210110338"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101665587","display_name":"Maria Chiara Rossi","orcid":"https://orcid.org/0000-0002-4262-5952","observed_orcids":["https://orcid.org/0000-0002-4262-5952"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maria Chiara Rossi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.9312,"has_fulltext":true,"cited_by_count":37,"citation_normalized_percentile":{"value":0.90906075,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"79","issue":"3","first_page":"184","last_page":"91"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/incretin-based-therapy","display_name":"incretin-based therapy","score":0.859000027179718},{"id":"https://openalex.org/keywords/clinical-inertia","display_name":"clinical inertia","score":0.875},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9990000128746033},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9399999976158142},{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":0.9039999842643738},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":1.0},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9589999914169312},{"id":"https://openalex.org/keywords/sitagliptin","display_name":"sitagliptin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/vildagliptin","display_name":"vildagliptin","score":1.0},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.7960000038146973},{"id":"https://openalex.org/keywords/metabolic-memory","display_name":"metabolic memory","score":0.7519999742507935},{"id":"https://openalex.org/keywords/treat-to-target","display_name":"treat-to-target","score":0.8289999961853027},{"id":"https://openalex.org/keywords/beta-cell-preservation","display_name":"beta-cell preservation","score":0.7680000066757202},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.8360000252723694},{"id":"https://openalex.org/keywords/weight-gain","display_name":"weight gain","score":0.8159999847412109}],"concepts":[{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.9092245101928711},{"id":"https://openalex.org/C2778881409","wikidata":"https://www.wikidata.org/wiki/Q1420402","display_name":"Incretin","level":4,"score":0.8097144365310669},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.795158863067627},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.6757798194885254},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.6713392734527588},{"id":"https://openalex.org/C2776453732","wikidata":"https://www.wikidata.org/wiki/Q421042","display_name":"Vildagliptin","level":4,"score":0.5848649740219116},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.555051326751709},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5273250937461853},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.5194253921508789},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.42502880096435547},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.33630892634391785},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24828866124153137},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.16693493723869324},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000068900","descriptor_name":"Sitagliptin Phosphate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077270","descriptor_name":"Exenatide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077597","descriptor_name":"Vildagliptin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D054795","descriptor_name":"Incretins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D054795","descriptor_name":"Incretins","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D054795","descriptor_name":"Incretins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":3,"locations":[{"id":"pmh:oai:mattioli1885journals.com:article/1246","doi":null,"is_oa":true,"landing_page_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/1246","pdf_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/download/1246/891","source":{"id":"https://openalex.org/S4393915150","display_name":"Acta bio-medica dell'Ateneo parmense/Acta biomedica","issn_l":"0392-4203","issn":["0392-4203","2531-6745"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","norway-1","poland-20","russia-white-list-2"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"0392-4203","raw_type":"info:eu-repo/semantics/article"},{"id":"pmid:19260377","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19260377","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Acta bio-medica : Atenei Parmensis","raw_type":"Comparative Study"},{"id":"mag:1491092293","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19260377","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":{"id":"pmh:oai:mattioli1885journals.com:article/1246","doi":null,"is_oa":true,"landing_page_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/1246","pdf_url":"https://www.mattioli1885journals.com/index.php/actabiomedica/article/download/1246/891","source":{"id":"https://openalex.org/S4393915150","display_name":"Acta bio-medica dell'Ateneo parmense/Acta biomedica","issn_l":"0392-4203","issn":["0392-4203","2531-6745"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","norway-1","poland-20","russia-white-list-2"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"0392-4203","raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1491092293.pdf","grobid_xml":"https://content.openalex.org/works/W1491092293.grobid-xml"},"referenced_works_count":28,"referenced_works":["https://openalex.org/W100598291","https://openalex.org/W2051462052","https://openalex.org/W2065690835","https://openalex.org/W2067710447","https://openalex.org/W2081276121","https://openalex.org/W2085862152","https://openalex.org/W2107648636","https://openalex.org/W2110020655","https://openalex.org/W2113322194","https://openalex.org/W2131343538","https://openalex.org/W2133452908","https://openalex.org/W2137808916","https://openalex.org/W2144611099","https://openalex.org/W2149194615","https://openalex.org/W2149762820","https://openalex.org/W2149896325","https://openalex.org/W2156888511","https://openalex.org/W2159205789","https://openalex.org/W2159969745","https://openalex.org/W2164416879","https://openalex.org/W2167039177","https://openalex.org/W2171294019","https://openalex.org/W2207468142","https://openalex.org/W2274300369","https://openalex.org/W2312161180","https://openalex.org/W2312778649","https://openalex.org/W2325198396","https://openalex.org/W2337454357"],"related_works":["https://openalex.org/W2184041836","https://openalex.org/W2094157061","https://openalex.org/W2274300369","https://openalex.org/W1964059797","https://openalex.org/W2149762820","https://openalex.org/W2075073089","https://openalex.org/W2077372959","https://openalex.org/W1701345","https://openalex.org/W2163133314","https://openalex.org/W1992081104"],"abstract_inverted_index":{"Maintaining":[0],"an":[1],"adequate":[2],"metabolic":[3],"control":[4,193],"is":[5,31,160],"still":[6],"a":[7,35,45,53,127,154,208,216],"challenge":[8],"in":[9,70,188,218],"many":[10,18],"patients":[11,119],"with":[12,97,162],"type":[13],"2":[14],"diabetes.":[15],"Among":[16],"the":[17,23,50,71,75,79,100,105,114,212,219],"factors":[19],"advocated":[20],"to":[21,25,77,179],"explain":[22],"failure":[24],"achieve":[26],"recommended":[27],"goals,":[28],"clinical":[29,109],"inertia":[30],"increasingly":[32],"recognised":[33],"as":[34],"primary":[36],"cause":[37],"of":[38,44,52,59,74,82,91,99,108,116,135,157,164,190,201,204,221],"poor":[39],"glycaemic":[40],"control.":[41],"The":[42,89,123],"existence":[43],"\"metabolic":[46],"memory\"":[47],"strongly":[48,112],"supports":[49],"adoption":[51],"more":[54],"aggressive":[55],"treat-to-target":[56],"approach,":[57],"instead":[58],"waiting":[60],"for":[61],"treatment":[62,131],"failure.":[63],"This":[64],"approach":[65],"may":[66,173,206],"be":[67],"particularly":[68],"important":[69],"initial":[72],"phases":[73],"disease,":[76],"slow":[78],"progressive":[80],"decline":[81],"beta-cell":[83,195],"function":[84,196],"and":[85,93,111,118,144,146,150,166,177,194,215],"improve":[86],"overall":[87],"outcomes.":[88],"fear":[90],"hypoglycaemia":[92,165],"weight":[94,167],"gain":[95],"associated":[96,161],"most":[98],"available":[101],"treatments":[102],"are":[103],"among":[104],"main":[106],"causes":[107],"inertia,":[110],"affect":[113],"attitudes":[115],"providers":[117],"toward":[120],"therapy":[121,175],"intensification.":[122],"incretin-based":[124,136],"therapies":[125],"represent":[126],"new":[128],"potential":[129],"goal-oriented":[130],"approach.":[132],"Two":[133],"classes":[134],"drugs":[137,205],"have":[138,153],"been":[139],"developed:":[140],"GLP-1":[141],"mimetics":[142],"(exenatide":[143],"liraglutide)":[145],"DPP-IV":[147],"inhibitors":[148],"(sitagliptin":[149],"vildagliptin).":[151],"Incretino-mimetics":[152],"peculiar":[155],"mechanism":[156],"action":[158],"that":[159],"lack":[163],"loss":[168],"or":[169],"neutrality;":[170],"these":[171],"characteristics":[172],"facilitate":[174],"intensification":[176],"help":[178],"attain":[180],"established":[181],"goals.":[182],"Furthermore,":[183],"they":[184],"can":[185],"induce":[186],"benefits":[187],"terms":[189],"post-prandial":[191],"hyperglicemia":[192],"preservation.":[197],"An":[198],"early":[199],"use":[200],"this":[202],"class":[203],"show":[207],"positive":[209],"impact":[210],"on":[211],"disease":[213],"progression":[214],"delay":[217],"need":[220],"insulin":[222],"injections.":[223]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}